Atrial fibrillation (AF) is the most common type of irregular heartbeat in clinical practice. It has been found to increase the risk of ischemic stroke by 5 times. To mitigate this risk, oral anticoagulation (OAC) is recommended for AF patients who have a CHA2DS2-VASc score of ≥2 in males or ≥3 in females [1,2]. The purpose of OAC is to reduce the chances of blood clot formation and improve the overall prognosis for AF patients. However, the use of OAC can increase the risk of bleeding events. Studies have shown that these bleeding events are associated with higher rates of cardiovascular complications and even death.
